|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.
|
29019447 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Radioimmunotherapies with monoclonal antibodies to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but U.S. Food and Drug Administration-approved radioimmunotherapies exclusively use radiolabeled murine antibodies, potentially limiting redosing.
|
29348316 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
|
15665303 |
2005 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Hepatitis B virus (HBV) reactivation has been noted in HBV surface antigen (HBsAg)-seronegative patients with CD20 B-cell non-Hodgkin lymphoma (NHL) undergoing rituximab treatment.
|
26986131 |
2016 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Rituximab (R) is an anti-CD20 monoclonal antibody which has become an essential component for the treatment of B-cell lymphomas.
|
27813427 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Rituximab (Rituxan; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA) is an effective agent for the treatment of CD20-positive B-cell lymphomas.
|
11225999 |
2000 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
CD20 is the first-line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias.
|
29079175 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, anti-CD20 therapy for B-cell lymphoma can result in intrinsic and extrinsic tumor resistance to further Ab treatment.
|
27354469 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, for the first time, we examined pro-apoptotic activity of SMIP-016 in combination with monoclonal anti-CD20 antibody, ofatumumab (HuMax-CD20) in de novo chronic lymphocytic leukaemia (CLL) cells and in different B-cell neoplasm-derived lines.
|
25154027 |
2014 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
In this issue of Blood, Lykken et al used an immunocompetent mouse model of B-cell lymphoma to discover an interesting new way in which these malignant cells can avoid being killed in the presence of anti-CD20 antibodies.
|
27081094 |
2016 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Multidrug resistance (MDR) in B-cell lymphomas still constitutes a major obstacle to the effectiveness of chemotherapy even in the anti-CD20 antibody therapy era.
|
23339364 |
2013 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
The T and B cell lymphomas and the nasopharyngeal carcinoma in nude mice were derived from human nasopharyngeal mucosa; this was proved by using human specific monoclonal antibodies to CD3 for T cells, to CD20 for B cells, and to epithelial membrane antigen for epithelial cells.
|
9829857 |
1998 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies targeting CD20 are central in the treatment of B-cell lymphomas.
|
31669559 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Human Serum Albumin-Based Drug-Free Macromolecular Therapeutics: Apoptosis Induction by Coiled-Coil-Mediated Cross-Linking of CD20 Antigens on Lymphoma B Cell Surface.
|
30259654 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Soon after the anti-CD20 monoclonal antibody rituximab began to change the management of indolent and aggressive B cell lymphomas, development of alternative antibodies - including chemoimmunoconjugates - was undertaken.
|
30668192 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
With the now well-accepted addition of rituximab (anti-CD20 antibody) to the typical large B-cell lymphoma chemotherapeutic regimen, a revalidation of any survival differences between the large B-cell lymphoma subgroups is necessary.
|
18181663 |
2008 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite wide use of the anti-CD20 monoclonal antibody rituximab in the treatment of B cell lymphomas, the mechanism by which it causes B cell depletion remains a subject of controversy.
|
12571855 |
2003 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings indicate that the number of NK cells in peripheral blood may affect the outcome of patients with B-cell non-Hodgkin lymphoma receiving anti-CD20-based immunochemotherapy.
|
31053601 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
CD107a degranulation and intracellular IFNγ production were also enhanced in CAR(+) exPBNK in response to CD20(+) B-NHL -: specific stimulation.
|
25492700 |
2015 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.
|
19773256 |
2010 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal anti-CD20 antibody (rituximab) is active, but not curative, therapy for B-cell non-Hodgkin's lymphoma.
|
15634664 |
2004 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies reported the therapeutic efficacy in mice bearing B-cell lymphoma xenografts following treatment with the anti-CD20-hIFNα fusion protein.
|
26398317 |
2015 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Paracentesis followed by immunophenotyping, karyotyping, and molecular studies allowed us to diagnose a small noncleaved B-cell lymphoma (CD20+, CD24+, CD10+, CD5-, CD23-, lambda+) with the t(8;22) (q24;q11) translocation and clonal rearrangement of the immunoglobulin heavy chain gene.
|
9013840 |
1997 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
We review here recent insights in the pathophysiology of B-NHL and discuss CD20 and three alternative membrane targets (B cell receptor, immune checkpoints PD-1/PD-L1, tetraspanin CD37) that are currently in the spotlight for B-NHL treatment.
|
28718418 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CD20Fab-LDM exerted potent cytotoxicity against CD20+ B-cell lymphoma cell lines in vitro (IC50: 10-30 pM) and in the Raji xenograft model.
|
20463754 |
2010 |